Biomind Labs Welcomes U.S. Executive Order on Psychedelic Research

Biomind Labs Inc. applauds a new executive order by President Trump, which accelerates research and access to psychedelic treatments in the United States. The order instructs federal agencies to fast-track clinical development of psychedelic therapies and expand research funding. These therapies could address mental health issues such as depression and PTSD.

The policy aligns with Biomind's mission to transform mental health treatment through next-generation psychedelic medicines. Biomind's clinical trials have shown promising results, particularly in addressing depression and anxiety in Alzheimer's patients. The order potentially shortens development timelines and attracts investments, benefiting Biomind's research and market strategy.

CEO Alejandro Antalich hails this as a paradigm shift in medicine. With the U.S. leading this change, Biomind anticipates global regulatory influence, expanding its reach and potentially transforming global mental healthcare.